The effect of indacaterol during an acute exacerbation of COPD

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 630-634

  Segreti, Andrea ^a   Fiori, Enrica ^b   Calzetta, Luigino ^c   Sabatini, Marco ^b   Segreti, Vincenzo ^b   Rogliani, Paola ^a   Cazzola, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SPIRITO SANTO HOSPITAL   (Italy)

^c IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

COPD; Exacerbation; Indacaterol; Salbutamol

Indexed keywords

INDACATEROL; IPRATROPIUM BROMIDE; LEVOFLOXACIN; METHYLPREDNISOLONE; SALBUTAMOL;

ACUTE CORONARY SYNDROME; ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE; AGED; ARTICLE; BREATHING RATE; CARBON DIOXIDE TENSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; LUNG FUNCTION; MALE; NEBULIZER; OXYGEN TENSION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPIROMETRY;

COPD; EXACERBATION; INDACATEROL; SALBUTAMOL;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; INDANS; IPRATROPIUM; LEVOFLOXACIN; MALE; METHYLPREDNISOLONE; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 84888013722     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.03.020     Document Type: Article

References (29)

1. Mackay A.J., Hurst J.R. COPD exacerbations: causes, prevention, and treatment. Med Clin North Am 2012, 96:789-809.
2. Global initiative for chronic obstructive lung disease (GOLD) global strategy for the diagnosis, management and prevention of COPD. Available from: ; [accessed 11.11.12]. http://www.goldcopd.org.
3. National Clinical Guideline Centre, London National Clinical Guideline Centre Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010, Available from:, [accessed 11.11.12]. http://guidance.nice.org.uk/CG101/Guidance/pdf/English.
4. Bernasconi M., Brandolese R., Poggi R., Manzin E., Rossi A. Dose-response effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intensive Care Med 1990, 16:108-114.
5. Emerman C.L., Cydulka R.K. Effect of different albuterol dosing regimens in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1997, 29:474-478.
6. Karpel J.P., Pesin J., Greenberg D., Gentry E. Acomparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990, 98:835-839.
7. 2 agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther 2003, 16:197-201.
8. Cazzola M., Di Perna F., D'Amato M., Califano C., Matera M.G., D'Amato G. Formoterol turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 2001, 95:917-921.
9. Cazzola M., Proietto A., Matera M.G. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010, 46:139-150.
10. Balint B., Watz H., Amos C., Owen R., Higgins M., Kramer B. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010, 5:311-318.
11. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
12. Brekke P.H., Omland T., Holmedal S.H., Smith P., Søyseth V. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J 2008, 31:563-570.
13. 2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005, 65:1595-1610.
14. Cazzola M., Imperatore F., Salzillo A., Di Perna F., Calderaro F., Imperatore A., et al. Cardiac effects of formoterol and salmeterol in patients suffering fromCOPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998, 114:411-415.
15. Høiseth A.D., Neukamm A., Karlsson B.D., Omland T., Brekke P.H., Søyseth V. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011, 66:775-781.
16. Martins C.S., Rodrigues M.J., Miranda V.P., Nunes J.P. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth J Med 2009, 67:341-349.
17. Cazzola M., Noschese P., De Michele F., D'Amato G., Matera M.G. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med 2006, 100:212-217.
18. Salpeter S.R., Thomas T.M., Salpeter E.E. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 2004, 125:2309-2321.
19. Worth H., Chung K.F., Felser J.M., Hu H., Rueegg P. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011, 105:571-579.
20. Donohue J.F., Singh D., Kornmann O., Lawrence D., Lassen C., Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011, 6:477-492.
21. Rutten F.H., Cramer M.J., Lammers J.W., Grobbee D.E., Hoes A.W. Heart failure and chronic obstructive pulmonary disease: an ignored combination?. Eur J Heart Fail 2006, 8:706-711.
22. Matera M.G., Martuscelli E., Cazzola M. Pharmacological modulation of β-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. Pulm Pharmacol Ther 2010, 23:1-8.
23. 2-adrenoceptor agonists. Am Heart J 2001, 142:E11.
24. Au D.H., Udris E.M., Fan V.S., Curtis J.R., McDonell M.B., Fihn S.D. Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003, 123:1964-1969.
25. Le Jemtel T.H., Padeletti M., Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. JAm Coll Cardiol 2007, 49:171-180.
26. Gariani K., Delabays A., Perneger T.V., Agoritsas T. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly 2011, 141:w1329.
27. Stolz D., Breidthardt T., Christ-Crain M., Bingisser R., Miedinger D., Leuppi J., et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008, 133:1088-1094.
28. 2-agonists on pulmonary artery pressure in COPD patients. Pulm Pharmacol Ther 2007, 20:258-264.
29. Tang W.H., Girod J.P., Lee M.J., Starling R.C., Young J.B., Van Lente F., et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003, 108:2964-2966.